These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33584953)

  • 1. Macrophage Migration Inhibitory Factor in Alopecia Areata and Vitiligo: A Case-Controlled Serological Study.
    Eldesouky F; Ibrahim AM; Sharaf SM
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):24-27. PubMed ID: 33584953
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris.
    Ma L; Xue HB; Guan XH; Shu CM; Zhang YJ; Zhang JH; An RZ
    Braz J Med Biol Res; 2013 May; 46(5):460-4. PubMed ID: 23797494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum level of macrophage migration inhibitory factor (MIF) in Egyptians with alopecia areata and its relation to the clinical severity of the disease.
    Younan DN; Agamia N; Elshafei A; Ebeid N
    J Clin Lab Anal; 2015 Jan; 29(1):74-9. PubMed ID: 24687398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of macrophage migration inhibitory factor (MIF) levels in serum and lesional skin of patients with alopecia areata.
    Salem SA; Asaad MK; Elsayed SB; Sehsah HM
    Int J Dermatol; 2016 Dec; 55(12):1357-1361. PubMed ID: 27420731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitiligo and alopecia areata: apples and oranges?
    Harris JE
    Exp Dermatol; 2013 Dec; 22(12):785-9. PubMed ID: 24131336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: a possible role in disease prevention.
    Rajabi F; Amoli MM; Robati RM; Almasi-Nasrabadi M; Jabalameli N
    Arch Dermatol Res; 2019 Oct; 311(8):589-594. PubMed ID: 31154458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress in patients with alopecia areata and vitiligo.
    Manolache L; Benea V
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):921-8. PubMed ID: 17659001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding autoimmunity of vitiligo and alopecia areata.
    Rork JF; Rashighi M; Harris JE
    Curr Opin Pediatr; 2016 Aug; 28(4):463-9. PubMed ID: 27191524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor as an incriminating agent in dermatological disorders.
    Pazyar N; Feily A; Yaghoobi R
    Indian J Dermatol; 2013 Mar; 58(2):157. PubMed ID: 23716815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colocalization of vitiligo and alopecia areata presenting as poliosis.
    Walker A; Mesinkovska NA; Boncher J; Tamburro J; Bergfeld WF
    J Cutan Pathol; 2015 Feb; 42(2):150-4. PubMed ID: 25388912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum levels of interleukin-17 in patients with alopecia areata and non-segmental vitiligo.
    Tomaszewska KA; Kozłowska M; Kaszuba A; Lesiak A; Narbutt J; Zalewska-Janowska AM
    Postepy Dermatol Alergol; 2022 Feb; 39(1):195-199. PubMed ID: 35369638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum brain-derived neurotrophic factor and vitamin D: Two concordant players controlling depression among alopecia areata and vitiligo patients: A case-control study.
    Dawoud NM; Rajab AZ; El-Hefnawy SM; El-Bayoumy AM; Salem AM; Seleit I
    J Cosmet Dermatol; 2023 Aug; 22(8):2343-2351. PubMed ID: 36999446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alexithymia in different dermatologic patients.
    Dehghani F; Dehghani F; Kafaie P; Taghizadeh MR
    Asian J Psychiatr; 2017 Feb; 25():42-45. PubMed ID: 28262172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alopecia areata and universalis in the Smyth chicken model for spontaneous autoimmune vitiligo.
    Smyth JR; McNeil M
    J Investig Dermatol Symp Proc; 1999 Dec; 4(3):211-5. PubMed ID: 10674368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease.
    Čeović R; Desnica L; Pulanić D; Serventi Seiwerth R; Ilić I; Grce M; Mravak Stipetić M; Klepac Pulanić T; Bilić E; Bilić E; Milošević M; Vrhovac R; Nemet D; Pavletic SZ
    Croat Med J; 2016 Jun; 57(3):229-38. PubMed ID: 27374824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Serum Levels of IFN-
    Tomaszewska K; Kozłowska M; Kaszuba A; Lesiak A; Narbutt J; Zalewska-Janowska A
    Oxid Med Cell Longev; 2020; 2020():5693572. PubMed ID: 32832001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrence of alopecia areata and vitiligo at the same anatomical site.
    Ozcan D; Cevlik Aydoğan F
    Australas J Dermatol; 2012 Aug; 53(3):e61-3. PubMed ID: 22881476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetics of pediatric cutaneous autoimmunity: The sister diseases vitiligo and alopecia areata.
    Silverberg N
    Clin Dermatol; 2022; 40(4):363-373. PubMed ID: 35183681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo.
    Galbraith GM; Miller D; Emerson DL
    Clin Immunol Immunopathol; 1988 Sep; 48(3):317-24. PubMed ID: 3042212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata.
    Shimizu T; Hizawa N; Honda A; Zhao Y; Abe R; Watanabe H; Nishihira J; Nishimura M; Shimizu H
    Genes Immun; 2005 Jun; 6(4):285-9. PubMed ID: 15815686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.